Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy

Editas Medicine remains on track to dose patients in 2026 in a Phase I/II trial of EDIT-401, an in vivo CRISPR therapy designed to lower LDL cholesterol by increasing LDL receptor production. EDIT-401 reduced LDL cholesterol by an average of 90% in non-human primates and also lowered lipoprotein(a) and ApoB, potentially offering greater LDL reduction than PCSK9-based therapies. The company expects initial safety data in the first quarter of 2027 and broader safety and efficacy data later that year. Editas reported $212 million in cash, which it expects will fund operations into the second half of 2028.

Editas Medicine NASDAQ: EDIT outlined its strategy as an in vivo gene-editing company and said it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, for lowering LDL cholesterol. Speaking at the Cantor Healthcare Conference, President and Chief Executive Officer Gilmore O’Neill said the company has completed its shift toward developing in vivo therapeutics using CRISPR editing. Editas is prioritizing programs designed to produce meaningful efficacy improvements, use mechanisms differentiated from other drug modalities, offer measurable biomarkers for rapid clinical decision-making, and potentially be delivered through a single infusion or injection.

EDIT-401 is designed to reduce LDL cholesterol by increasing levels of the LDL receptor, which removes LDL cholesterol from circulation. O’Neill said the program uses CRISPR-Cas9 and CRISPR-Cas12 editing tools to mimic naturally occurring gain-of-function genetic variants rather than applying gene editing to mechanisms accessible through antibodies, antisense therapies or siRNA medicines. The company’s approach is based on a naturally occurring LDLR variant identified in an Icelandic family whose members had low LDL cholesterol levels but were otherwise healthy, according to O’Neill. The variant involved a deletion in the three-prime untranslated region of the LDLR gene, removing microRNA binding sites and extending the messenger RNA’s half-life, enabling production of more LDL receptor protein. Editas selected a guide RNA pair that does not perfectly replicate the naturally occurring deletion but was more potent in exploratory work, O’Neill said.

In non-human primate studies, EDIT-401 produced a mean 90% reduction in LDL cholesterol, along with reductions in other atherogenic lipoproteins including lipoprotein(a) and ApoB. The company said it observed at least a sixfold increase in LDL receptor expression in the liver in those studies. O’Neill contrasted the strategy with approaches targeting PCSK9, saying PCSK9 inhibition may face a ceiling effect because it prevents degradation of LDL receptors already produced by liver cells rather than directly increasing LDLR production. He said reductions of roughly 50% to 60% with PCSK9-directed approaches have been transformative but that Editas aims to produce greater LDL lowering through a different mechanism.

Editas has submitted documentation to Australia’s Human Research Ethics Committee, or HREC, for EDIT-401 and is answering questions related to items such as the informed-consent form and starting dose. O’Neill said the company remains on schedule to dose patients this year, though he declined to specify the exact timing before receiving HREC clearance. If clearance were received, site activation could require a couple of months before the first patient is dosed, he sa...